Skip to content
Screener

Kestra Medical Technologies KMTS Q3 2026 earnings

Reported March 17, 2026 · After market close

Revenue$24.6MBeat by $1.7M
EPS-$0.61Miss by $0.01
Revenue estimate$22.9M
EPS estimate-$0.60

Next report

Dec 10, 2026 (in 2 months)
Revenue estimate$32.0M
EPS estimate-$0.61

Financials

Q3 2026

Income statement

See full
Revenue$24.6M+62.7%
Gross profit$12.9M+97.1%
Operating income-$34.8M-68.8%
Net income-$34.2M-58.8%
EPS (diluted)-$0.61+51.2%

Balance sheet

See full
Cash & equivalents$291.3M+436%
Total debt$43.8M—
Total assets$379.3M—

Cash flow

See full
Operating cash flow-$18.4M-2.1%
CapEx$9.8M+141%
Free cash flow-$28.2M-27.7%

Valuation & ratios

Valuation

as of 01/31/26
See full
Market cap$1.44B—
Enterprise value$1.19B—
P/S17.2×—

Profitability

See full
Gross margin48.8%+15.1pp
Operating margin-171.5%+12.9pp
Net margin-173%+0.8pp
FCF margin-142.9%-25.3pp

Returns & leverage

See full
Current ratio7.3×—

FAQ

When did Kestra Medical Technologies report Q3 2026 earnings?
Kestra Medical Technologies (KMTS) reported Q3 2026 earnings on March 17, 2026 after market close.
What were Kestra Medical Technologies's Q3 2026 revenue and EPS?
Kestra Medical Technologies reported revenue of $24.6M and eps of $-0.61 for Q3 2026.
Did Kestra Medical Technologies beat estimates in Q3 2026?
Revenue beat the consensus estimate of $22.9M by $1.7M. EPS missed the consensus estimate of $-0.60 by $0.01.
How did Kestra Medical Technologies's Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 0.0% from $24.6M a year earlier and eps grew 0.0% from $-0.61.
Where can I find Kestra Medical Technologies's Q3 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-110720) and the 10-Q periodic report (0001193125-26-111205) directly on SEC EDGAR. The filing index links above go to sec.gov.